| pubmed-article:15378505 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15378505 | lifeskim:mentions | umls-concept:C0035335 | lld:lifeskim |
| pubmed-article:15378505 | lifeskim:mentions | umls-concept:C0253023 | lld:lifeskim |
| pubmed-article:15378505 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15378505 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15378505 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15378505 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15378505 | pubmed:dateCreated | 2004-10-6 | lld:pubmed |
| pubmed-article:15378505 | pubmed:abstractText | The importance of the Fas-Fas ligand (FasL) mechanism for the immune evasion by tumors provided a strong rationale for the examination of FasL expression in retinoblastoma. In an earlier publication, the authors reported that invasive retinoblastomas decreased Fas expression. Because to the authors' knowledge there is not much information regarding the effect of FasL expression on retinoblastoma, the authors studied the expression of FasL in retinoblastoma and correlated it with invasiveness. | lld:pubmed |
| pubmed-article:15378505 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15378505 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15378505 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15378505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15378505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15378505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15378505 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15378505 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15378505 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:BiswasJyotirm... | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:KrishnakumarS... | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:IyerAnitaA | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:ShanmugamMahe... | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:KandalamMalli... | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:MohanAdithiA | lld:pubmed |
| pubmed-article:15378505 | pubmed:author | pubmed-author:VenkatesanNal... | lld:pubmed |
| pubmed-article:15378505 | pubmed:copyrightInfo | (c) 2004 American Cancer Society. | lld:pubmed |
| pubmed-article:15378505 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15378505 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15378505 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:15378505 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15378505 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15378505 | pubmed:pagination | 1672-6 | lld:pubmed |
| pubmed-article:15378505 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:meshHeading | pubmed-meshheading:15378505... | lld:pubmed |
| pubmed-article:15378505 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15378505 | pubmed:articleTitle | Expression of Fas ligand in retinoblastoma. | lld:pubmed |
| pubmed-article:15378505 | pubmed:affiliation | Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India. drkrishnakumar_2000@yahoo.com | lld:pubmed |
| pubmed-article:15378505 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15378505 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
